Crossmark

Comparison of sequential and joint nonlinear mixed effects modeling of tumor kinetics and survival following Durvalumab treatment in patients with metastatic urothelial carcinoma

Crossref DOI link: https://doi.org/10.1007/s10928-023-09848-w

Published Online: 2023-03-12

Published Print: 2023-08

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Chen, Ting

Zheng, Yanan

Roskos, Lorin

Mager, Donald E.
Funding

Funding for this research was provided by:

AstraZeneca,United States
License Information

Text and Data Mining valid from 2023-03-12

Version of Record valid from 2023-03-12
More Information

Article History

Received: 17 July 2022

Accepted: 9 February 2023

First Online: 12 March 2023

Declarations

:

: T.C. reports no competing interests that might be perceived to influence the results and/or discussion reported in this paper.

Document is current

Any future updates will be listed below